Corcept Therapeutics Inc. (CORT)
Corcept Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of severe and rare metabolic and psychiatric disorders. It is best known for its portfolio of cortisol receptor modulators, including mifepristone, which is approved for the treatment of Cushing's syndrome and psychotic mood disorders. The company's pipeline also includes other compounds targeting conditions related to cortisol dysregulation.
Company News
The global high- and low-grade serous ovarian cancer market is expected to grow at a CAGR of 7.9% from 2020 to 2034, driven by the launch of emerging therapies. The US market is the largest, capturing nearly USD 1.9 billion in 2024. Key companies working on innovative ovarian cancer drugs include Verastem Oncology, Corcept Therapeutics, AstraZene...
Corcept Therapeutics shares soared 6.5% due to strong demand for its drug Korlym and the expected filing of a new drug application for its lead candidate relacorilant. The company's earnings and revenue growth expectations also contribute to the share price rally.
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeut...
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.
